- TRADE NAME: Rozlytrek (Genentech)
- INDICATIONS:
Treatment of adult patients with metastatic non-small cell lung cancer whose tumors are ROS1-positive.
Treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation.
Treatment of solid tumors that are metastatic or have progressed following treatment or have no satisfactory alternative therapy.
- CLASS: Anaplastic lymphoma kinase (ALK) inhibitor, Kinase inhibitor, Tropomyosin receptor kinase inhibitor
- HALF-LIFE: 20 hours; 40 hours (major metabolite)
- FDA APPROVAL DATE: 08/15/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Moderate and Strong CYP3A Inducers, Moderate and strong CYP3A inhibitors - PREGNANCY: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception. Advise not to breastfeed.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 11/26/2024
